RPRX - Dividend announcements

NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence That Each of MSCI's Four Business Segments is Under Pressure, Resulting in Client Retention Challenges Expresses Concern That MSCI Uses Aggressive Accounting and Financial Reporting to Place Greater Emphasis on Adjusted EPS While Cash Flow Stagnates and the Dividend Growth Rate Plunges Believes MSCI's $949 Million Acquisition of Real Capital Analytics Should be Evaluated for Impairment After Client Losses and Rising Competition Observes That MSCI Exhibits a Pattern of Opaque Deal-Making with People and Entities Related to Morgan Stanley and Questions if They are in the

Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou